{'fraction_non_alphanumeric': 0.020366598778004074, 'fraction_numerical': 0.010183299389002037, 'mean_word_length': 5.648648648648648, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine

Biological significance of ELK1, a transcriptional factor whose phosphorylation is necessary for c‐fos proto‐oncogene activation, in prostate cancer remains far from fully understood. In this study, we aim to investigate the role of ELK1 in tumor growth as well as the efficacy of a selective α1A‐adrenergic blocker, silodosin, in ELK1 activity in prostate cancer cells.